Global Oxcarbazepine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Oxcarbazepine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Oxcarbazepine, sold under the brand name Trileptal among others, is a medication used to treat epilepsy and bipolar disorder. It is a structural derivative of carbamazepine, with an extra oxygen atom to the benzylcarboxamide group. The presence of an extra oxygen atom in the structure reduces the susceptibility of the drug to hepatic metabolism, leading to prolonged pharmacological action or half life of the drug.
Oxcarbazepine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Oxcarbazepine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Pediatric Use (Aged 2-4 years, 4-16 years) and Adult Use are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Oxcarbazepine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Oxcarbazepine key manufacturers include Novartis (Trileptal), Supernus Pharmaceuticals (Oxtellar XR), Sun Pharm, Ranbaxy Pharmaceuticals, Jubilant Generics, Taro Pharmaceuticals, Mylan, Stada Group and Glenmark Pharmaceuticals, etc. Novartis (Trileptal), Supernus Pharmaceuticals (Oxtellar XR), Sun Pharm are top 3 players and held % sales share in total in 2022.
Oxcarbazepine can be divided into Tablets (150mg, 300mg, 600mg) and Oral Suspension, etc. Tablets (150mg, 300mg, 600mg) is the mainstream product in the market, accounting for % sales share globally in 2022.
Oxcarbazepine is widely used in various fields, such as Pediatric Use (Aged 2-4 years, 4-16 years) and Adult Use, etc. Pediatric Use (Aged 2-4 years, 4-16 years) provides greatest supports to the Oxcarbazepine industry development. In 2022, global % sales of Oxcarbazepine went into Pediatric Use (Aged 2-4 years, 4-16 years) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oxcarbazepine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novartis (Trileptal)
Supernus Pharmaceuticals (Oxtellar XR)
Sun Pharm
Ranbaxy Pharmaceuticals
Jubilant Generics
Taro Pharmaceuticals
Mylan
Stada Group
Glenmark Pharmaceuticals
ANI Pharmaceuticals
Teva Pharmaceutical
Roxane Laboratories
Nobelpharma
Apotex
Nexgen pharma
Amneal Pharmaceuticals
Hikma Pharmaceuticals
Jamp Pharma
Neuraxpharm
Orion Corporation
Sihuan Pharm
Humanwell Healthcare
Huikang Pharmaceutical
Segment by Type
Tablets (150mg, 300mg, 600mg)
Oral Suspension
Pediatric Use (Aged 2-4 years, 4-16 years)
Adult Use
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Oxcarbazepine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Oxcarbazepine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Oxcarbazepine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Oxcarbazepine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Oxcarbazepine introduction, etc. Oxcarbazepine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Oxcarbazepine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Oxcarbazepine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Oxcarbazepine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Pediatric Use (Aged 2-4 years, 4-16 years) and Adult Use are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Oxcarbazepine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Oxcarbazepine key manufacturers include Novartis (Trileptal), Supernus Pharmaceuticals (Oxtellar XR), Sun Pharm, Ranbaxy Pharmaceuticals, Jubilant Generics, Taro Pharmaceuticals, Mylan, Stada Group and Glenmark Pharmaceuticals, etc. Novartis (Trileptal), Supernus Pharmaceuticals (Oxtellar XR), Sun Pharm are top 3 players and held % sales share in total in 2022.
Oxcarbazepine can be divided into Tablets (150mg, 300mg, 600mg) and Oral Suspension, etc. Tablets (150mg, 300mg, 600mg) is the mainstream product in the market, accounting for % sales share globally in 2022.
Oxcarbazepine is widely used in various fields, such as Pediatric Use (Aged 2-4 years, 4-16 years) and Adult Use, etc. Pediatric Use (Aged 2-4 years, 4-16 years) provides greatest supports to the Oxcarbazepine industry development. In 2022, global % sales of Oxcarbazepine went into Pediatric Use (Aged 2-4 years, 4-16 years) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oxcarbazepine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novartis (Trileptal)
Supernus Pharmaceuticals (Oxtellar XR)
Sun Pharm
Ranbaxy Pharmaceuticals
Jubilant Generics
Taro Pharmaceuticals
Mylan
Stada Group
Glenmark Pharmaceuticals
ANI Pharmaceuticals
Teva Pharmaceutical
Roxane Laboratories
Nobelpharma
Apotex
Nexgen pharma
Amneal Pharmaceuticals
Hikma Pharmaceuticals
Jamp Pharma
Neuraxpharm
Orion Corporation
Sihuan Pharm
Humanwell Healthcare
Huikang Pharmaceutical
Segment by Type
Tablets (150mg, 300mg, 600mg)
Oral Suspension
Segment by Application
Pediatric Use (Aged 2-4 years, 4-16 years)
Adult Use
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Oxcarbazepine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Oxcarbazepine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Oxcarbazepine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Oxcarbazepine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Oxcarbazepine introduction, etc. Oxcarbazepine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Oxcarbazepine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices